Ridinilazole for the treatment of Clostridioides difficile infection
Sign Up to like & getrecommendations! Published in 2019 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2019.1582640
Abstract: ABSTRACT Introduction: Ridinilazole is a novel antibiotic being developed for the treatment of Clostridioides difficile infection (CDI). Ridinilazole has completed two phase II trials and phase III trials which are denoted Ri-CoDIFy 1 and 2,… read more here.
Keywords: trial; cdi; treatment clostridioides; clinicaltrials gov ... See more keywords